Conditions: Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer; GI Carcinoma; Lung Cancer
Interventions: Drug: Standard of Care Chemotherapy; Procedure: Video-Assisted Thoracic Surgery (VATS); Procedure: Lobectomy; Radiation: Consolidative Radiation; Radiation: Ablation Treatment; Procedure: Resection or Excision; Procedure: Peritonectomy; Other: Transarterial Radioembolization
Sponsor: University of Chicago
Not yet recruiting
Feeds
20859 items (20859 unread) in 74 feeds
Acinar Cell Carcinoma
(201 unread)
Acinic Cell Carcinoma
(104 unread)
Adenoid Cystic Carcinoma
(367 unread)
Adrenal Gland Cancer
(1718 unread)
Ampulla Of Vater
(213 unread)
Anal Cancer
(1799 unread)
Angiosarcoma
(359 unread)
Appendix Cancer
(450 unread)
Bile Duct Cancer
(2698 unread)
Brain and CNS
(2597 unread)
Carcinoid
(671 unread)
Endocrine/Neuroendocrine
(2404 unread)
Gall Bladder Cancer
(1146 unread)
Hemangioendothelioma
(506 unread)
Hepatoblastoma
(366 unread)
Pancreas
(416 unread)
Phyllodes
(215 unread)
PMP and Mucinous Tumors
(242 unread)
Rhabdomyosarcoma
(772 unread)
Sarcoma
(3615 unread)
Trial - Cholangiocarcinoma (73 unread)
-
Study Comparing Standard of Care Therapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Posted: June 18th, 2021, 2:00pm GMT
-
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
Posted: June 11th, 2021, 2:00pm GMT
Condition: Biliary Tract Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma
Posted: June 9th, 2021, 2:00pm GMT
Conditions: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration
Intervention: Drug: TT-00420
Sponsor: TransThera Biosciences Co., Ltd
Not yet recruiting -
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Posted: June 4th, 2021, 2:00pm GMT
Conditions: Mesothelioma; Glioblastoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Breast Cancer; Ovarian Cancer; Cervical Cancer; Endocervical Cancer; Colorectal Cancer; Esophageal Cancer
Interventions: Drug: NGM707; Drug: NGM707 plus pembrolizumab
Sponsor: NGM Biopharmaceuticals, Inc
Recruiting -
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Posted: June 3rd, 2021, 2:00pm GMT
Condition: Solid Tumor
Intervention: Drug: utidelone injection
Sponsors: Beijing Biostar Technologies, Ltd; Chengdu Biostar Pharmaceuticals, Ltd
Recruiting -
EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction
Posted: May 24th, 2021, 2:00pm GMT
Condition: Malignant Biliary Obstruction
Intervention: Procedure: Biliary drainage
Sponsor: Mansoura University
Recruiting -
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Posted: May 20th, 2021, 2:00pm GMT
Conditions: HRD; Cholangiocarcinoma; Metastatic Cancer
Interventions: Drug: Niraparib; Drug: Dostarlimab
Sponsors: Walid Shaib, MD; Emory University; GlaxoSmithKline
Not yet recruiting -
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Posted: May 18th, 2021, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Floxuridine (FUDR); Device: Implanted Medical Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Biomarker Discovery in Patients With Advanced Biliary Tract Cancer
Posted: May 4th, 2021, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: nab-paclitaxel plus gemcitabine-cisplatin
Sponsors: CHA University; Dong-A Pharmaceutical
Recruiting -
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
Posted: April 30th, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Combination Product: Radiotherapy
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Recruiting -
Photodynamic Therapy for Cholangiocarcinoma
Posted: April 26th, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma Non-resectable
Intervention: Drug: Hematoporphyrin
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Posted: April 23rd, 2021, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Recurrence; Cholangiocarcinoma; Gall Bladder Cancer
Interventions: Drug: S-1; Drug: Capecitabine
Sponsor: Fudan University
Recruiting -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor
Posted: April 21st, 2021, 2:00pm GMT
Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma
Interventions: Drug: ELI-002 (Dose Escalation); Drug: ELI-002 (at the RP2D); Other: Observation
Sponsor: Elicio Therapeutics
Recruiting -
Liver Transplantation in Patients With Incidental Hepatocellular-cholangiocarcinoma and Intrahepatic Cholangiocarcinoma: A Single-center Experience
Posted: April 19th, 2021, 2:00pm GMT
Condition: Adult Combined Hepatocellular-Cholangiocarcinoma
Intervention: Procedure: liver transplantation
Sponsor: Istanbul Demiroglu Bilim University
Recruiting -
Prognosis of Nutritional Status for Surgical Peri Hilar Cholangiocarcinoma
Posted: April 15th, 2021, 2:00pm GMT
Condition: Perihilar Cholangiocarcinoma
Intervention: Other: Nutritional evaluation
Sponsor: Central Hospital, Nancy, France
Recruiting -
Cholangioscopy or Conventional Techniques for Indeterminate Biliary Stenosis
Posted: April 12th, 2021, 2:00pm GMT
Condition: Malignant Biliary Stenosis
Intervention: Procedure: endoscopic retrograde cholangiopancreatography with cholangioscopy in the first procedure of ERCP
Sponsor: Frederic PRAT, MD, PhD
Recruiting -
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Posted: April 7th, 2021, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Transarterial Chemoembolization; Apatinib; PD-1 Antibody
Intervention: Combination Product: DEB-TACE combined with apatinib and PD-1 antibody
Sponsor: Sichuan Cancer Hospital and Research Institute
Not yet recruiting -
Neoadjuvant PDT in the Treatment of Cholangiocarcinoma
Posted: April 1st, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma Resectable
Interventions: Procedure: Neoadjuvant PDT + radical surgery; Procedure: Radical surgery
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting -
Endoscopic Ultrasound-Guided Gastroenterostomy for Malignant Gastric Outlet Obstruction
Posted: March 23rd, 2021, 2:00pm GMT
Condition: Malignant Gastric Outlet Obstruction
Intervention: Procedure: EUS-guided gastroenterostomy
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting -
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Posted: March 17th, 2021, 2:00pm GMT
Conditions: MSI-H Colorectal Cancer; Melanoma; Anal Carcinoma; Mesothelioma; Triple Negative Breast Cancer; Lung Adenocarcinoma; Cholangiocarcinoma; Cervical Carcinoma; Kidney Clear Cell Carcinoma; Stomach Adenocarcinoma; Esophageal Adenocarcinoma; Uterine Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Sarcoma; Lung Squamous Cell Carcinoma; Bladder Carcinoma; Thyroid Carcinoma; Hepatocellular Carcinoma; Uveal Melanoma; HER2-positive Breast Cancer; Pancreatic Adenocarcinoma; Squamous Esophageal Carcinoma; Ovarian Serous Cystadenocarcinoma; Uterine Carcinosarcoma; Small Cell Lung Cancer; Hormone Receptor Positive / HER2-negative Breast Cancer; Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation; Colorectal Adenocarcinoma; Prostate Adenocarcinoma; Carcinoma of Unknown Primary; Other Histology
Intervention: Drug: Spartalizumab
Sponsors: SOLTI Breast Cancer Research Group; Novartis
Recruiting -
REMS Combined With TAI for Unresectable HC
Posted: March 16th, 2021, 2:00pm GMT
Condition: Unresectable Hilar Cholangiocarcinoma
Interventions: Procedure: REMS+TAI; Procedure: SEMS+TAI
Sponsor: Zhongda Hospital
Not yet recruiting -
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
Posted: March 16th, 2021, 2:00pm GMT
Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Colorectal Cancer; Lung Cancer; Pancreatic Cancer; Cholangiocarcinoma; Head and Neck Cancer
Intervention: Drug: WM-S1-030
Sponsors: Wellmarker Bio; Covance
Not yet recruiting -
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
Posted: March 12th, 2021, 3:00pm GMT
Condition: Platinum-Sensitive Biliary Tract Cancer
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Pamiparib; Drug: Temozolomide
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting -
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Posted: March 12th, 2021, 3:00pm GMT
Condition: Solid Tumor
Intervention: Drug: IDE397
Sponsor: IDEAYA Biosciences
Recruiting -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Posted: March 11th, 2021, 3:00pm GMT
Conditions: Uveal Melanoma; Cutaneous Melanoma; BAP1 Gene Mutation; Renal Cell Carcinoma; Mesothelioma; Hepatocellular Carcinoma; Cholangiocarcinoma; Meningioma Atypical
Intervention:
Sponsor: Mohamed Abdel-Rahman
Recruiting -
PD-1 Antibody（Tislelizumab） Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection
Posted: March 4th, 2021, 3:00pm GMT
Condition: Cholangiocarcinoma, Intrahepatic
Interventions: Drug: Capecitabine; Drug: PD-1 Antibody（Tislelizumab）
Sponsor: Fudan University
Recruiting -
I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma
Posted: March 3rd, 2021, 3:00pm GMT
Condition: Hilar Cholangiocarcinoma
Interventions: Device: I-125 seeds loaded stent; Device: Normal stent
Sponsor: Xuzhou Central Hospital
Not yet recruiting -
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Posted: February 22nd, 2021, 3:00pm GMT
Conditions: HER2-negative Breast Cancer; Gastric Adenocarcinoma; Cholangiocarcinoma; Pancreatic Cancer
Interventions: Drug: Niraparib; Drug: Anlotinib
Sponsor: Beijing Cancer Hospital
Not yet recruiting -
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
Posted: February 22nd, 2021, 3:00pm GMT
Conditions: Pancreatic Cancer; Bile Duct Cancer; Ampulla of Vater Cancer
Intervention: Procedure: pancreaticoduodenectomy
Sponsor: State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
Recruiting -
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Posted: February 19th, 2021, 3:00pm GMT
Condition: Isocitrate Dehydrogenase Gene Mutation
Intervention: Drug: HMPL-306
Sponsor: Hutchison Medipharma Limited
Recruiting -
Clinical Validation of an Immunocytochemistry Method Using MARS1
Posted: February 18th, 2021, 3:00pm GMT
Condition: Bile Duct Obstruction, Extrahepatic
Intervention: Diagnostic Test: Cytology staining
Sponsor: Gangnam Severance Hospital
Not yet recruiting -
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Posted: February 15th, 2021, 3:00pm GMT
Conditions: Primary Sclerosing Cholangitis; PSC; Cholangiocarcinoma
Intervention:
Sponsors: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting -
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
Posted: January 27th, 2021, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma
Intervention: Drug: Bintrafusp alfa
Sponsors: AIO-Studien-gGmbH; Merck Serono GmbH, Germany
Not yet recruiting -
Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma
Posted: January 22nd, 2021, 3:00pm GMT
Conditions: Cholangiocarcinoma; Interventional Imaging
Intervention: Procedure: Irreversible electroporation
Sponsors: Poitiers University Hospital; Sport & Collection 2019
Not yet recruiting -
Difficult Biliary Cannulation in Patients With Distal Malignant Biliary Obstruction: an Underestimated Problem
Posted: January 14th, 2021, 3:00pm GMT
Condition: Biliary Condition
Intervention: Procedure: Endsocopic Retrograde ColangioPancreatography (ERCP)
Sponsor: Istituto Clinico Humanitas
Recruiting -
Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors W
Posted: December 21st, 2020, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Intervention: Drug: STP705
Sponsors: Sirnaomics; Translational Drug Development
Recruiting -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Posted: December 9th, 2020, 3:00pm GMT
Conditions: HER2-positive; Adenocarcinoma; Bile Duct Cancer; Biliary Tract Cancer; Bladder Cancer; Breast Cancer; Breast Neoplasm; Carcinoma, Ductal; Carcinoma, Hepatocellular; Cancer; Lung Cancer, Non-Small-Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carcinoma, Squamous; Carcinoma, Transitional Cell; Colorectal Cancer; Esophagogastric Junction Neoplasms; Inflammatory Breast Cancer; Stomach Neoplasms; Malignant Neoplasms; Ovarian Neoplasms; Pancreatic Cancer; HER2-positive Solid Tumors; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification; Prostate Cancer; Head and Neck Cancer; Endometrial Cancer; Lung Cancer, Small Cell
Intervention: Biological: CT-0508
Sponsor: Carisma Therapeutics Inc
Recruiting -
Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies
Posted: November 24th, 2020, 3:00pm GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym022; Drug: Sym023
Sponsor: Symphogen A/S
Recruiting -
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Posted: September 23rd, 2020, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Intervention: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Recruiting -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Posted: July 30th, 2020, 2:00pm GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVB Gastric Cancer AJCC v8; Pathologic Stage III Gastric Cancer AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastric Cancer AJCC v8; Pathologic Stage IIIC Gastric Cancer AJCC v8; Pathologic Stage IV Gastric Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Penile Cancer AJCC v8; Stage IIIA Pleural Malignant Mesothelioma AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Penile Cancer AJCC v8; Stage IIIB Pleural Malignant Mesothelioma AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Neoadjuvant Therapy in Biliary Adenocarcinoma
Posted: July 21st, 2020, 2:00pm GMT
Conditions: Cholangiocarcinoma; Biliary Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Short course ChemoRT
Sponsor: Jordan Kharofa
Recruiting -
Afatinib in Advanced NRG1-Rearranged Malignancies
Posted: June 1st, 2020, 2:00pm GMT
Condition: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Intervention: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Not yet recruiting -
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
Posted: May 22nd, 2020, 2:00pm GMT
Conditions: Pancreatic Adenocarcinoma; Pancreatic Cysts; Pancreatic Endocrine Tumors; Chronic Pancreatitis; Cholangiocarcinoma, Extrahepatic; Ampullary Adenocarcinoma; Duodenal Adenocarcinoma
Interventions: Procedure: Robotic pancreaticoduodenectomy; Procedure: Open pancreaticoduodenectomy
Sponsors: Ruijin Hospital; Intuitive Surgical
Recruiting -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Posted: May 12th, 2020, 2:00pm GMT
Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Pancreatic Cancer; Lung Cancer; Head and Neck Cancer; Breast Cancer; Kidney Cancer; Colorectal Cancer; Bladder Cancer; Ovarian Cancer; Sarcoma; Gallbladder Cancer; Bile Duct Cancer; Esophageal Cancer; Uterine Cancer; Cholangiocarcinoma; Prostate Cancer
Intervention: Drug: Seribantumab
Sponsor: Elevation Oncology
Recruiting -
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
Posted: February 5th, 2020, 3:00pm GMT
Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Dexamethasone; Drug: Floxuridine; Device: Implanted Medical Device; Drug: Irinotecan; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Recruiting -
Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Biliary Stricture; Jaundice, Obstructive
Interventions: Device: Biliary brushing with the RX Cytology brush, Boston Scientific; Device: Biliary brushing with the Infinity® brush, US Endoscopy
Sponsor: Société Française d'Endoscopie Digestive
Recruiting -
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Posted: January 27th, 2020, 3:00pm GMT
Condition: Radiotherapy
Intervention: Radiation: Adaptative MR-Guided Stereotactic Body Radiotherapy
Sponsor: Centre Georges Francois Leclerc
Recruiting -
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Posted: January 23rd, 2020, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: E7090
Sponsor: Eisai Co., Ltd.
Recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Recruiting -
Safety of ABM-1310 in Patients With Advanced Solid Tumors
Posted: December 9th, 2019, 3:00pm GMT
Conditions: Advanced Solid Tumor; BRAF V600 Mutation
Interventions: Drug: ABM-1310; Drug: Cobimetinib
Sponsor: ABM Therapeutics, Inc.
Recruiting -
Futibatinib in Patients With Specific FGFR Aberrations
Posted: December 6th, 2019, 3:00pm GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Recruiting -
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
Posted: November 15th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: NUC-1031; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: NuCana plc
Recruiting -
Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma (CCA) Harboring FGFR2 Gene Rearrangements
Posted: September 18th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
Interventions: Drug: TAS-120; Drug: Cisplatin/Gemcitabine
Sponsor: Taiho Oncology, Inc.
Recruiting -
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Posted: September 12th, 2019, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Available -
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
Posted: September 3rd, 2019, 2:00pm GMT
Conditions: Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: Trifluridine/Tipiracil
Sponsors: Sunnybrook Health Sciences Centre; Taiho Pharma Canada, Inc.
Recruiting -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: Bintrafusp alfa; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
The Registry of Oncology Outcomes Associated With Testing and Treatment
Posted: July 22nd, 2019, 2:00pm GMT
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Not yet recruiting -
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Posted: April 29th, 2019, 2:00pm GMT
Condition: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: Drug: ZW25 (Zanidatamab); Drug: Capecitabine; Drug: Cisplatin; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Bevacizumab; Drug: Gemcitabine
Sponsor: Zymeworks Inc.
Recruiting -
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Posted: January 29th, 2019, 3:00pm GMT
Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting -
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients
Posted: November 7th, 2018, 3:00pm GMT
Condition: Cancer
Intervention: Biological: FP-1305
Sponsor: Faron Pharmaceuticals Ltd
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Posted: September 4th, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting -
Fluorescence Image Guided Surgery in Cholangiocarcinoma
Posted: August 8th, 2018, 2:00pm GMT
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: near infrared (NIR) fluorescence imaging
Sponsor: University Medical Center Groningen
Recruiting -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Posted: May 7th, 2018, 2:00pm GMT
Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Colorectal Carcinoma; Non-small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma; Mesothelioma; Neuroendocrine Carcinoma; Cervical Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of the Anus; Castration-Resistant Prostate Carcinoma; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Basal Cell Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Thymoma; Thymic Carcinoma; Squamous Cell Carcinoma of the Penis; Vulvar Carcinoma; Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy; Malignant Adnexal Neoplasms; Non-squamous Cell Salivary Gland Carcinoma
Intervention: Biological: XmAb20717
Sponsors: Xencor, Inc.; ICON plc
Recruiting -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Posted: March 2nd, 2018, 3:00pm GMT
Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer; COVID; Myelofibrosis; Myeloproliferative Neoplasm; Myeloproliferative Disorders; Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Myelodysplastic Syndromes
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting -
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma
Posted: December 19th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Interventions: Drug: ABC294640; Drug: Hydroxychloroquine Sulfate 200 MG
Sponsor: RedHill Biopharma Limited
Recruiting -
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Posted: November 13th, 2017, 3:00pm GMT
Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Recruiting -
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Posted: July 26th, 2017, 2:00pm GMT
Conditions: Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Recruiting -
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Posted: July 2nd, 2017, 2:00pm GMT
Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; TESARO/GlaxoSmithKline
Recruiting -
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Posted: February 20th, 2017, 3:00pm GMT
Conditions: Breast Cancer; Head and Neck Cancer; Squamous Cell Carcinoma; Lymphoma; Pancreatic Cancer; Liver Cancer; Colon Cancer; Lung Cancer; Bile Duct Cancer; Chordoma of Sacrum; Sarcoma
Interventions: Drug: INT230-6; Biological: anti-PD-1 antibody; Biological: anti-CTLA-4 antibody
Sponsors: Intensity Therapeutics, Inc.; Merck Sharp & Dohme Corp.; Bristol-Myers Squibb
Recruiting -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: February 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; Servier
Recruiting -
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Posted: August 29th, 2016, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Stage IV Liver Cancer; Stage IVA Liver Cancer; Stage IVB Liver Cancer; Vascular Thrombosis
Interventions: Procedure: Computed Tomography; Procedure: Single Photon Emission Computed Tomography; Drug: Technetium Tc-99m Sulfur Colloid
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting -
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
Posted: December 10th, 2015, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cirrhosis; Hepatocellular Carcinoma; Metastatic Malignant Neoplasm in the Liver
Interventions: Other: Laboratory Biomarker Analysis; Procedure: Magnetic Resonance Imaging; Radiation: Radiation Therapy; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting